Cancellations by sponsors

This database shows cancellations of Australian Register of Therapeutic Goods entries requested by sponsors.

Last updated

23 December 2025

Find out more at Information about cancellations requested by the sponsor - regulatory actions.

72580 result(s) found, displaying 36601 to 36625

HOSPIRA ROPIVACAINE HYDROCHLORIDE INJECTION ropivacaine hydrochloride (as monohydrate) 400 mg/200 mL solution for injection bag Cancelled under Section 30(1)(c) of the Act

26 November 2020

Cancellation by sponsor

Requested by Pfizer Australia Pty Ltd
HOSPIRA ROPIVACAINE HYDROCHLORIDE INJECTION ropivacaine hydrochloride (as monohydrate) 50 mg/10 mL solution for injection ampoule Cancelled under Section 30(1)(c) of the Act

26 November 2020

Cancellation by sponsor

Requested by Pfizer Australia Pty Ltd
HOSPIRA ROPIVACAINE HYDROCHLORIDE INJECTION ropivacaine hydrochloride (as monohydrate) 75 mg/10 mL solution for injection ampoule Cancelled under Section 30(1)(c) of the Act

26 November 2020

Cancellation by sponsor

Requested by Pfizer Australia Pty Ltd
Olympus Australia Pty Ltd - Needle, aspirating, single use Cancelled under Section 41GL(d) of the Act

26 November 2020

Cancellation by sponsor

Requested by Olympus Australia Pty Ltd
Point Blank Medical Pty Ltd - Mask, surgical, single use Cancelled under Section 41GL(d) of the Act

26 November 2020

Cancellation by sponsor

Requested by Point Blank Medical Pty Ltd
Post-Age Pty Ltd - Airway protection face mask Cancelled under Section 41GL(d) of the Act

26 November 2020

Cancellation by sponsor

Requested by Post-Age Pty Ltd
Post-Age Pty Ltd - Public N95 respirator Cancelled under Section 41GL(d) of the Act

26 November 2020

Cancellation by sponsor

Requested by Post-Age Pty Ltd
ROPIVACAINE PFIZER ropivacaine hydrochloride solution for injection 200 mg/100 mL bag Cancelled under Section 30(1)(c) of the Act

26 November 2020

Cancellation by sponsor

Requested by Pfizer Australia Pty Ltd
ROPIVACAINE PFIZER ropivacaine hydrochloride solution for injection 400 mg/200 mL bag Cancelled under Section 30(1)(c) of the Act

26 November 2020

Cancellation by sponsor

Requested by Pfizer Australia Pty Ltd
ANSIC Pty Ltd - Mask, surgical, single use Cancelled under Section 41GL(d) of the Act

25 November 2020

Cancellation by sponsor

Requested by ANSIC Pty Ltd
Beaver-Visitec International Australia Pty Ltd - Syringe, hypodermic, metered-delivery Cancelled under Section 41GL(d) of the Act

25 November 2020

Cancellation by sponsor

Requested by Beaver-Visitec International Australia Pty Ltd
Fortress Procurement Pty Ltd - Nitrile examination/treatment glove, non-powdered Cancelled under Section 41GL(d) of the Act

25 November 2020

Cancellation by sponsor

Requested by Fortress Procurement Pty Ltd
InNatal Cancelled under Section 30(1)(c) of the Act

25 November 2020

Cancellation by sponsor

Requested by FIT-BioCeuticals Limited
InNatal plus Iron Cancelled under Section 30(1)(c) of the Act

25 November 2020

Cancellation by sponsor

Requested by FIT-BioCeuticals Limited
MPL-BUPRENORPHINE/NALOXONE 0.7/0.18 buprenorphine (as HCl) 0.7 mg / naloxone (as HCl dihydrate) 0.18 mg sublingual tablet blister pack Cancelled under Section 30(1)(c) of the Act

25 November 2020

Cancellation by sponsor

Requested by Mundipharma Pty Ltd
MPL-BUPRENORPHINE/NALOXONE 11.4/2.9 buprenorphine (as HCl) 11.4 mg / naloxone (as HCl dihydrate) 2.9 mg sublingual tablet blister pack Cancelled under Section 30(1)(c) of the Act

25 November 2020

Cancellation by sponsor

Requested by Mundipharma Pty Ltd
MPL-BUPRENORPHINE/NALOXONE 1.4/0.36 buprenorphine (as HCl) 1.4 mg / naloxone (as HCl dihydrate) 0.36 mg sublingual tablet blister pack Cancelled under Section 30(1)(c) of the Act

25 November 2020

Cancellation by sponsor

Requested by Mundipharma Pty Ltd
MPL-BUPRENORPHINE/NALOXONE 2.9/0.71 buprenorphine (as HCl) 2.9 mg / naloxone (as HCl dihydrate) 0.71 mg sublingual tablet blister pack Cancelled under Section 30(1)(c) of the Act

25 November 2020

Cancellation by sponsor

Requested by Mundipharma Pty Ltd
MPL-BUPRENORPHINE/NALOXONE 5.7/1.4 buprenorphine (as HCl) 5.7 mg / naloxone (as HCl dihydrate) 1.4 mg sublingual tablet blister pack Cancelled under Section 30(1)(c) of the Act

25 November 2020

Cancellation by sponsor

Requested by Mundipharma Pty Ltd
MPL-BUPRENORPHINE/NALOXONE 8.6/2.1 buprenorphine (as HCl) 8.6 mg / naloxone (as HCl dihydrate) 2.1 mg sublingual tablet blister pack Cancelled under Section 30(1)(c) of the Act

25 November 2020

Cancellation by sponsor

Requested by Mundipharma Pty Ltd
SONWAY AUSTRALIA PTY LTD - Mask Cancelled under Section 41GL(d) of the Act

25 November 2020

Cancellation by sponsor

Requested by SONWAY AUSTRALIA PTY LTD
Surgeons Choice Australia Pty Ltd - Cover, cable/lead/sensor/probe Cancelled under Section 41GL(d) of the Act

25 November 2020

Cancellation by sponsor

Requested by Surgeons Choice Australia Pty Ltd
Sydicare Pty Ltd - Gown, isolation, single use Cancelled under Section 41GL(d) of the Act

25 November 2020

Cancellation by sponsor

Requested by Sydicare Pty Ltd
Sydicare Pty Ltd - Mask, surgical, single use Cancelled under Section 41GL(d) of the Act

25 November 2020

Cancellation by sponsor

Requested by Sydicare Pty Ltd
Aunique Beauty Boost Cancelled under Section 30(1)(c) of the Act

24 November 2020

Cancellation by sponsor

Requested by Austrad Group Pty Ltd

Last updated

23 December 2025

Sub menu

Product regulation

Safety and shortages

Resources and guidance

Business services

Cancellations by sponsors

Filter results

Decision type

Date of effect

HOSPIRA ROPIVACAINE HYDROCHLORIDE INJECTION ropivacaine hydrochloride (as monohydrate) 400 mg/200 mL solution for injection bag Cancelled under Section 30(1)(c) of the Act

HOSPIRA ROPIVACAINE HYDROCHLORIDE INJECTION ropivacaine hydrochloride (as monohydrate) 50 mg/10 mL solution for injection ampoule Cancelled under Section 30(1)(c) of the Act

HOSPIRA ROPIVACAINE HYDROCHLORIDE INJECTION ropivacaine hydrochloride (as monohydrate) 75 mg/10 mL solution for injection ampoule Cancelled under Section 30(1)(c) of the Act

Olympus Australia Pty Ltd - Needle, aspirating, single use Cancelled under Section 41GL(d) of the Act

Point Blank Medical Pty Ltd - Mask, surgical, single use Cancelled under Section 41GL(d) of the Act

Post-Age Pty Ltd - Airway protection face mask Cancelled under Section 41GL(d) of the Act

Post-Age Pty Ltd - Public N95 respirator Cancelled under Section 41GL(d) of the Act

ROPIVACAINE PFIZER ropivacaine hydrochloride solution for injection 200 mg/100 mL bag Cancelled under Section 30(1)(c) of the Act

ROPIVACAINE PFIZER ropivacaine hydrochloride solution for injection 400 mg/200 mL bag Cancelled under Section 30(1)(c) of the Act

ANSIC Pty Ltd - Mask, surgical, single use Cancelled under Section 41GL(d) of the Act

Beaver-Visitec International Australia Pty Ltd - Syringe, hypodermic, metered-delivery Cancelled under Section 41GL(d) of the Act

Fortress Procurement Pty Ltd - Nitrile examination/treatment glove, non-powdered Cancelled under Section 41GL(d) of the Act

InNatal Cancelled under Section 30(1)(c) of the Act

InNatal plus Iron Cancelled under Section 30(1)(c) of the Act

MPL-BUPRENORPHINE/NALOXONE 0.7/0.18 buprenorphine (as HCl) 0.7 mg / naloxone (as HCl dihydrate) 0.18 mg sublingual tablet blister pack Cancelled under Section 30(1)(c) of the Act

MPL-BUPRENORPHINE/NALOXONE 11.4/2.9 buprenorphine (as HCl) 11.4 mg / naloxone (as HCl dihydrate) 2.9 mg sublingual tablet blister pack Cancelled under Section 30(1)(c) of the Act

MPL-BUPRENORPHINE/NALOXONE 1.4/0.36 buprenorphine (as HCl) 1.4 mg / naloxone (as HCl dihydrate) 0.36 mg sublingual tablet blister pack Cancelled under Section 30(1)(c) of the Act

MPL-BUPRENORPHINE/NALOXONE 2.9/0.71 buprenorphine (as HCl) 2.9 mg / naloxone (as HCl dihydrate) 0.71 mg sublingual tablet blister pack Cancelled under Section 30(1)(c) of the Act

MPL-BUPRENORPHINE/NALOXONE 5.7/1.4 buprenorphine (as HCl) 5.7 mg / naloxone (as HCl dihydrate) 1.4 mg sublingual tablet blister pack Cancelled under Section 30(1)(c) of the Act

MPL-BUPRENORPHINE/NALOXONE 8.6/2.1 buprenorphine (as HCl) 8.6 mg / naloxone (as HCl dihydrate) 2.1 mg sublingual tablet blister pack Cancelled under Section 30(1)(c) of the Act

SONWAY AUSTRALIA PTY LTD - Mask Cancelled under Section 41GL(d) of the Act

Surgeons Choice Australia Pty Ltd - Cover, cable/lead/sensor/probe Cancelled under Section 41GL(d) of the Act

Sydicare Pty Ltd - Gown, isolation, single use Cancelled under Section 41GL(d) of the Act

Sydicare Pty Ltd - Mask, surgical, single use Cancelled under Section 41GL(d) of the Act

Aunique Beauty Boost Cancelled under Section 30(1)(c) of the Act

Is there anything wrong with this page?

Site notifications

Cancellations by sponsors

Filter results

Decision type

Date of effect

Is there anything wrong with this page?